CIK 0002012593 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Rapport Therapeutics, Inc.
Sign in to watch- Ticker
- RAPP
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 880724208
- Phone
- 857-321-8020
- Business address
- 99 HIGH STREET, SUITE 2100, BOSTON, MA, 02110
- Former names
- Rapport Therapeutics, Inc.
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- 4 Grant or award Director acquired 1,428,571 shares (grant or award)
- 4 Open-market buy Director bought 969,480 shares at $21.00 ($20,359,080)
- 8-K Event Material agreement · Results of operations · New debt or obligation · Unregistered share sale
- 424B5 Offering Prospectus
- 424B5 Offering Prospectus
- 305B2 Other 305B2
- FWP Offering Free Writing Prospectus
- FWP Offering Free Writing Prospectus
- FWP Offering Free Writing Prospectus
- FWP Offering Free Writing Prospectus
- 424B5 Offering Prospectus
- 424B5 Offering Prospectus
- 4 Planned sale Chief Executive Officer sold 2,210 shares at $29.16 ($64,448)
- 4 Open-market buy Director bought 3,600 shares at $27.35 ($98,478)
- 4 Open-market buy Director bought 3,680 shares at $27.08 ($99,636)
- 4 Open-market buy Director bought 3,789 shares at $26.39 ($99,992)
- 4 Open-market buy Director bought 35,714 shares at $27.28 ($974,278)
- 4 Open-market buy Director bought 9,411 shares at an average $26.45 ($248,891)
Page 1 of 13 · 253 filings